|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030956,
umls-concept:C0039195,
umls-concept:C0205263,
umls-concept:C0206394,
umls-concept:C0206397,
umls-concept:C0442821,
umls-concept:C0871261,
umls-concept:C1524063,
umls-concept:C1541478,
umls-concept:C1623051,
umls-concept:C1704632,
umls-concept:C1705822,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-3-6
|
|
pubmed:abstractText |
Delivery of tumor-associated Ag-derived peptides in a high immunogenic form represents one of the key issues for effective peptide-based cancer vaccine development. We report herein the ability of nonpathogenic filamentous bacteriophage fd virions to deliver HLA-A2-restricted MAGE-A10(254-262)- or MAGE-A3(271-279)-derived peptides and to elicit potent specific CTL responses in vitro and in vivo. Interestingly, human anti-MAGE-A3(271-279)-specific CTLs were able to kill human MAGE-A3(+) tumor cells, even if these cells naturally express a low amount of MAGE-A3(271-279) peptide-HLA epitope surface complexes and are usually not recognized by CTLs generated by conventional stimulation procedures. MAGE-A3(271-279)-specific/CD8(+) CTL clones were isolated from in vitro cultures, and their high avidity for Ag recognition was assessed. Moreover, in vivo tumor protection assay showed that vaccination of humanized HHD (HLA-A2.1(+)/H2-D(b+)) transgenic mice with phage particles expressing MAGE-A3(271-279)-derived peptides hampered tumor growth. Overall, these data indicate that engineered filamentous bacteriophage virions increase substantially the immunogenicity of delivered tumor-associated Ag-derived peptides, thus representing a novel powerful system for the development of effective peptide-based cancer vaccines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
180
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3719-28
|
|
pubmed:meshHeading |
pubmed-meshheading:18322177-Amino Acid Sequence,
pubmed-meshheading:18322177-Animals,
pubmed-meshheading:18322177-Antigen Presentation,
pubmed-meshheading:18322177-Antigens, Neoplasm,
pubmed-meshheading:18322177-Bacteriophage M13,
pubmed-meshheading:18322177-Cell Line, Tumor,
pubmed-meshheading:18322177-Clone Cells,
pubmed-meshheading:18322177-Cytotoxicity, Immunologic,
pubmed-meshheading:18322177-Genetic Engineering,
pubmed-meshheading:18322177-HLA-DR Antigens,
pubmed-meshheading:18322177-Humans,
pubmed-meshheading:18322177-Lymphocyte Activation,
pubmed-meshheading:18322177-Mice,
pubmed-meshheading:18322177-Mice, Inbred C57BL,
pubmed-meshheading:18322177-Mice, Transgenic,
pubmed-meshheading:18322177-Molecular Sequence Data,
pubmed-meshheading:18322177-Neoplasm Proteins,
pubmed-meshheading:18322177-Peptide Fragments,
pubmed-meshheading:18322177-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:18322177-Virion
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
|
|
pubmed:affiliation |
Institute of Protein Biochemistry, Consiglio Nazionale delle Ricerche, Naples, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
